Liu is recognized for his innovative use of neutron scattering techniques to identify the origin of the problematic high viscosity found in many concentrated solutions of monoclonal antibodies (mAbs). High viscosities cause severe manufacturing difficulties and inhibit distribution of mAbs drugs after injection. Liu's research has influenced the next generation of therapeutics and promises to significantly expand the applicability of mAbs, which have proven successful in treating many diseases, including some cancers, achieving a global market value of over $40 billion to date.